Clinical Drug Investigation

, Volume 31, Issue 1, pp 1–14 | Cite as

Diagnosis and Management of Autoimmune Myasthenia Gravis

Review Article


Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease.



The author thanks Rod McNab and Mary Hines from inScience Communications, a Wolters Kluwer business, who provided medical writing services funded by MEDA Group, Spain. The author also acknowledges the supportive discussions at Eurobiobank (supported by Translational Research in Europe — Assessment and Treatment of Neuromuscular Diseases [TREAT-NMD]) and the support of the Italian Ministry of Education. The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Tiedt TN, Albuquerque EX, Hudson CS, et al. Neostigmineinduced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology. J Pharmacol Exp Ther 1978 May; 205(2): 326–39PubMedGoogle Scholar
  2. 2.
    Boonyapisit K, Kaminski HJ, Ruff RL. Disorders of neuromuscular junction ion channels. Am J Med 1999 Jan; 106(1): 97–113PubMedCrossRefGoogle Scholar
  3. 3.
    Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction. Muscle Nerve 2006 Apr; 33(4): 445–61PubMedCrossRefGoogle Scholar
  4. 4.
    Drachman DB. Myasthenia gravis. N Engl J Med 1994 Jun 23; 330(25): 1797–810PubMedCrossRefGoogle Scholar
  5. 5.
    Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001 Mar; 7(3): 365–8PubMedCrossRefGoogle Scholar
  6. 6.
    Witzemann V. Development of the neuromuscular junction. Cell Tissue Res 2006 Nov; 326(2): 263–71PubMedCrossRefGoogle Scholar
  7. 7.
    Harper CM. Congenital myasthenic syndromes. Semin Neurol 2004 Mar; 24(1): 111–23PubMedCrossRefGoogle Scholar
  8. 8.
    Phillips 2nd LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996 Nov; 47(5): 1233–8PubMedCrossRefGoogle Scholar
  9. 9.
    Phillips 2nd H. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003 Sep; 998: 407–12PubMedCrossRefGoogle Scholar
  10. 10.
    Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006 Sep; 253Suppl. 5: V2–8PubMedCrossRefGoogle Scholar
  11. 11.
    Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J 2004 Dec; 80(950): 690–700PubMedCrossRefGoogle Scholar
  12. 12.
    Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238–43PubMedCrossRefGoogle Scholar
  13. 13.
    Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003 Mar 25; 60(6): 1024–6PubMedCrossRefGoogle Scholar
  14. 14.
    Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003 Aug; 74(8): 1105–8PubMedCrossRefGoogle Scholar
  15. 15.
    Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989 Oct; 52(10): 1121–7PubMedCrossRefGoogle Scholar
  16. 16.
    Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008 Feb; 37(2): 141–9PubMedCrossRefGoogle Scholar
  17. 17.
    Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007; 2: 44PubMedCrossRefGoogle Scholar
  18. 18.
    Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007; 21(6): 473–81PubMedCrossRefGoogle Scholar
  19. 19.
    Myasthenia Gravis Foundation of America. Myasthenia gravis: a manual for the health care provider [online]. Available from URL: http: // MGFA_ProfessionalManual.pdf [Accessed 2008 Nov 18]Google Scholar
  20. 20.
    Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998 May 13; 841: 769–72PubMedCrossRefGoogle Scholar
  21. 21.
    Jaretzki 3rd A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000 Jul 12; 55(1): 16–23PubMedCrossRefGoogle Scholar
  22. 22.
    Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988 Jul; 26(7): 724–35PubMedCrossRefGoogle Scholar
  23. 23.
    Burns TM, Conaway MR, Cutter GR, et al. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008 Aug; 38(2): 957–63PubMedCrossRefGoogle Scholar
  24. 24.
    Mullins LL, Carpentier MY, Paul RH, et al. Diseasespecific measure of quality of life for myasthenia gravis. Muscle Nerve 2008 Aug; 38(2): 947–56PubMedCrossRefGoogle Scholar
  25. 25.
    Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001 Oct; 22(5): 363–9PubMedCrossRefGoogle Scholar
  26. 26.
    Paul RH, Nash JM, Cohen RA, et al. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24(4): 512–6PubMedCrossRefGoogle Scholar
  27. 27.
    Rostedt A, Padua L, Stalberg EV. Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in myasthenia gravis patients. Clin Neurophysiol 2005 Sep; 116(9): 2058–64PubMedCrossRefGoogle Scholar
  28. 28.
    Rostedt A, Padua L, Stalberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur JNeurol 2006 Feb; 13(2): 191–3CrossRefGoogle Scholar
  29. 29.
    Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988 Apr; 77(4): 443–5PubMedCrossRefGoogle Scholar
  30. 30.
    Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997 Feb; 244(2): 112–8PubMedCrossRefGoogle Scholar
  31. 31.
    Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977 Jan; 7(1): 36–43PubMedCrossRefGoogle Scholar
  32. 32.
    Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985 Dec; 48(12): 1246–52PubMedCrossRefGoogle Scholar
  33. 33.
    Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004 Jun 8; 62(11): 2132–3PubMedCrossRefGoogle Scholar
  34. 34.
    Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003 Oct; 126 (Pt 10): 2304–11PubMedCrossRefGoogle Scholar
  35. 35.
    Shigemoto K, Kubo S, Jie C, et al. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 2008; 1132: 93–8PubMedCrossRefGoogle Scholar
  36. 36.
    Martignago S, Fanin M, Albertini E, et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 2009 Feb; 35(1): 103–10PubMedCrossRefGoogle Scholar
  37. 37.
    Rostedt Punga A, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006 Jul; 117(7): 1434–43PubMedCrossRefGoogle Scholar
  38. 38.
    Le Panse R, Cizeron-Clairac G, Cuvelier M, et al. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 135–42PubMedCrossRefGoogle Scholar
  39. 39.
    Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA 2005 Apr 20; 293(15): 1906–14PubMedCrossRefGoogle Scholar
  40. 40.
    Bever Jr CT, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983 Nov; 14(5): 516–9PubMedCrossRefGoogle Scholar
  41. 41.
    Chaudhuri A, Behan PO. Myasthenic crisis. QJM 2009 Feb; 102(2): 97–107PubMedCrossRefGoogle Scholar
  42. 42.
    Panda S, Goyal V, Behari M, et al. Myasthenic crisis: a retrospective study. Neurol India 2004 Dec; 52(4): 453–6PubMedGoogle Scholar
  43. 43.
    Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. Crit Care Med 1997 Jul; 25(7): 1228–35PubMedCrossRefGoogle Scholar
  44. 44.
    Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997 Jun; 41(6): 789–96PubMedCrossRefGoogle Scholar
  45. 45.
    Murthy JM, Meena AK, Chowdary GV, et al. Myasthenic crisis: clinical features, complications and mortality. Neurol India 2005 Mar; 53(1): 37–40; discussion 40PubMedCrossRefGoogle Scholar
  46. 46.
    Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007 Mar 13; 68(11): 837–41PubMedCrossRefGoogle Scholar
  47. 47.
    Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008 Feb; 21(1): 8–15PubMedCrossRefGoogle Scholar
  48. 48.
    Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006 Jul; 16(7): 459–67PubMedCrossRefGoogle Scholar
  49. 49.
    Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008; 1132: 84–92PubMedCrossRefGoogle Scholar
  50. 50.
    Bau V, Hanisch F, Hain B, et al. Ocular involvement in MuSK antibody-positive myasthenia gravis [in German]. Klin Monbl Augenheilkd 2006 Jan; 223(1): 81–3PubMedCrossRefGoogle Scholar
  51. 51.
    Cikes N, Momoi MY, Williams CL, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988 May; 63(5): 474–81PubMedGoogle Scholar
  52. 52.
    Dumitru D. Part IV, Section 25: Neuromuscular junction disorders: electrodiagnostic medicine. 2nd ed. Philadelphia (PA): Hanley & Belfus, 2001Google Scholar
  53. 53.
    AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001 Sep; 24(9): 1236–8CrossRefGoogle Scholar
  54. 54.
    Howard Jr JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994 May; 12(2): 305–30PubMedGoogle Scholar
  55. 55.
    Zivkovic SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol 2005 Dec; 45(4): 248–61PubMedGoogle Scholar
  56. 56.
    Stickler DE, Sanders DB. Single-fiber EMG, 2009 [online]. Available from URL: article/1141438-overview [Accessed 2010 Mar 9]Google Scholar
  57. 57.
    Burns TM, Conaway M, Sanders DB. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010 May 4; 74(18): 1434–40PubMedCrossRefGoogle Scholar
  58. 58.
    Burns TM, Conaway MR, Cutter GR, et al. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008 Dec; 38(6): 1553–62PubMedCrossRefGoogle Scholar
  59. 59.
    Genkins G, Sivak M, Tartter PI. Treatment strategies in myasthenia gravis. Ann N Y Acad Sci 1993 Jun 21; 681: 603–8PubMedCrossRefGoogle Scholar
  60. 60.
    Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934; 1: 1200–1CrossRefGoogle Scholar
  61. 61.
    McEachern D. Prostigmine in myasthenia gravis. Can Med AssocJ 1935; 310-1Google Scholar
  62. 62.
    Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006 Jul; 13(7): 691–9PubMedCrossRefGoogle Scholar
  63. 63.
    Havard CW, Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990 Jan; 39(1): 66–73PubMedCrossRefGoogle Scholar
  64. 64.
    Aquilonius SM, Eckernas SA, Hartvig P, et al. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 1983 Oct; 46(10): 929–35PubMedCrossRefGoogle Scholar
  65. 65.
    Schumm F, Gaertner HJ, Wiatr G, et al. Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance [in German]. Fortschr Neurol Psychiatr 1985 Jun; 53(6): 201–11PubMedCrossRefGoogle Scholar
  66. 66.
    Osserman KE. Progress report on mestinon bromide (pyridostigmine bromide).Am J Med 1955 Nov; 19(5): 737–9PubMedCrossRefGoogle Scholar
  67. 67.
    Data on file, Meda Group, 2010Google Scholar
  68. 68.
    eMC. Mestinon (pyridostigmine bromide) 60 mg tablets: summary of product characteristics. 2007 [online]. Available from URL: 865/SPC/Mestinon+60mg+Tablets/ [Accessed 2009 May 29]Google Scholar
  69. 69.
    Milner-Brown HS, Mellenthin M, Sharma ML, et al. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis. Neurology 1987 May; 37(5): 800–3PubMedCrossRefGoogle Scholar
  70. 70.
    Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988 Aug; 67(8): 775–8PubMedCrossRefGoogle Scholar
  71. 71.
    eMC. Neostigmine bromide tablets: summary of product characteristics. 2001 [online]. Available from URL: http:// [Accessed 2009 Apr 6]Google Scholar
  72. 72.
    eMC. Neostigmine methylsulphate BP 2.5mg in 1mL: summary of product characteristics. 2008 [online]. Available from URL: 20888/SPC/Neostigmine+Methylsulphate+Injection+BP+ 2.5mg+in+1ml+ (hameln)/ [Accessed 2009 Jun 2]Google Scholar
  73. 73.
    Schwab RS, Marshall CK, Timberlake W. WIN 8077 in treatment of myasthenia gravis; use of N,N’-bis (2-diethylaminoethyl) oxamide bis-2-chlorobenzyl chloride in fifty patients. J Am Med Assoc 1955 Jun 25; 158(8): 625–8PubMedCrossRefGoogle Scholar
  74. 74.
    sanofi-synthelabo. Mytelase® (ambenonium chloride) prescribing information. 2008 July [online]. Available from URL: html [Accessed 2010 Jun 25]Google Scholar
  75. 75.
    Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984 Mar; 15(3): 291–8PubMedCrossRefGoogle Scholar
  76. 76.
    Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; (2): CD002828Google Scholar
  77. 77.
    Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry 2009 Jan; 80(1): 5–6; discussion 6PubMedCrossRefGoogle Scholar
  78. 78.
    Palace J, Newsom-Davis J, Lecky B. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998 Jun; 50(6): 1778–83PubMedCrossRefGoogle Scholar
  79. 79.
    Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; (4): CD005224Google Scholar
  80. 80.
    Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987 Mar 19; 316(12): 719–24PubMedCrossRefGoogle Scholar
  81. 81.
    Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997 Sep; 244(9): 542–7PubMedCrossRefGoogle Scholar
  82. 82.
    Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 May; 47(2-3): 85–118PubMedCrossRefGoogle Scholar
  83. 83.
    Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003 Nov 25; 61(10): 1438–40PubMedCrossRefGoogle Scholar
  84. 84.
    Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008 Aug 5; 71(6): 400–6PubMedCrossRefGoogle Scholar
  85. 85.
    Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008 Aug 5; 71(6): 394–9CrossRefGoogle Scholar
  86. 86.
    Hehir MK, Burns TM, Alpers JP, et al. Long-term experience with mycophenolate mofetil (MMF) in myasthenia gravis (MG): retrospective analysis of 103 patients [abstract]. Neurology 2009; 72(11 Suppl. 3): A440Google Scholar
  87. 87.
    Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002; (4): CD002275Google Scholar
  88. 88.
    Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; (1): CD002277Google Scholar
  89. 89.
    Chan A, Lee DH, Linker R, et al. Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 2007 Nov; 254(11): 1604–6PubMedCrossRefGoogle Scholar
  90. 90.
    Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006 Apr; 33(4): 575–80PubMedCrossRefGoogle Scholar
  91. 91.
    Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007 Jul; 254(7): 968–9PubMedCrossRefGoogle Scholar
  92. 92.
    Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with monarsen. Ann N Y Acad Sci 2008; 1132: 283–90PubMedCrossRefGoogle Scholar
  93. 93.
    Gronseth GS, Barohn RJ. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 2002 May; 4(3): 203–9PubMedCrossRefGoogle Scholar
  94. 94.
    Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Jul 12; 55(1): 7–15PubMedCrossRefGoogle Scholar
  95. 95.
    Aghajanzadeh M, Khoshrang H, Mohammadzadeh A, et al. Thymectomy for myasthenia gravis: prognostic factors in 70 patients. Asian Cardiovasc Thorac Ann 2007 Oct; 15(5): 371–5PubMedGoogle Scholar
  96. 96.
    Abt PL, Patel HJ, Marsh A, et al. Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience. J Am Coll Surg 2001 Apr; 192(4): 459–64PubMedCrossRefGoogle Scholar
  97. 97.
    Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999 Jun; 67(6): 1563–7PubMedCrossRefGoogle Scholar
  98. 98.
    Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003 Jun 24; 60(12): 1978–80PubMedCrossRefGoogle Scholar
  99. 99.
    Magee MJ, Mack MJ. Surgical approaches to the thymus in patients with myasthenia gravis. Thorac Surg Clin 2009 Feb; 19(1): 83–9, viiPubMedCrossRefGoogle Scholar
  100. 100.
    Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve 2010 Mar; 41(3): 370–4PubMedCrossRefGoogle Scholar
  101. 101. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy. 2009 November 9 [online]. Available from URL: momatous&rank=1 [Accessed 2010 Jun 25]Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of NeurosciencesUniversity of PadovaPadovaItaly
  2. 2.IRCSS S. CamilloVeniceItaly

Personalised recommendations